GW 501516

GW 501516

• CAS Number: 317318-70-0
• UNSPSC Description: GW 501516 (GW 1516) is a PPARδ agonist with an EC50 of 1.1 nM[1].
• Target Antigen: Autophagy; PPAR
• Type: Reference compound
• Related Pathways: Autophagy;Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
• Applications: Cancer-programmed cell death
• Field of Research: Metabolic Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/GW-501516.html
• Purity: 99.43
• Solubility: DMSO : ≥ 100 mg/mL
• Smiles: OC(COC1=CC=C(C=C1C)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)C)=O
• Molecular Weight: 453.50
• References & Citations: [1]Wei ZL, et al. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta. J Org Chem. 2003 Nov 14;68(23):9116-8.|[2]Mosti MP, et al. Effects of the peroxisome proliferator-activated receptor (PPAR)-δ agonist GW 501516 on bone and muscle in ovariectomized rats. Endocrinology. 2014 Jun;155(6):2178-89.|[3]Yang X, et al. GW 501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice. PLoS One. 2011;6(9):e25271.|[4]Chen W, et al. A metabolomic study of the PPARδ agonist GW 501516 for enhancing running endurance in Kunming mice. Sci Rep. 2015 May 6;5:9884.|[5]Ji Y, et al. PPARβ/δ Agonist GW501516 Inhibits Tumorigenicity of Undifferentiated Nasopharyngeal Carcinoma in C666-1 Cells by Promoting Apoptosis. Front Pharmacol. 2018 Jun 28;9:648.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Phase 4